Details

Autor(en) / Beteiligte

• Self, Wesley H
• Tenforde, Mark W
• Rhoads, Jillian P
• Gaglani, Manjusha
• Ginde, Adit A
• Douin, David J
• Olson, Samantha M
• Talbot, H Keipp
• Casey, Jonathan D
• Mohr, Nicholas M
• Zepeski, Anne
• McNeal, Tresa
• Ghamande, Shekhar
• Gibbs, Kevin W
• Files, D Clark
• Hager, David N
• Shehu, Arber
• Prekker, Matthew E
• Erickson, Heidi L
• Gong, Michelle N
• Mohamed, Amira
• Henning, Daniel J
• Steingrub, Jay S
• Peltan, Ithan D
• Brown, Samuel M
• Martin, Emily T
• Monto, Arnold S
• Khan, Akram
• Hough, Catherine L
• Busse, Laurence W
• Ten Lohuis, Caitlin C
• Duggal, Abhijit
• Wilson, Jennifer G
• Gordon, Alexandra June
• Qadir, Nida
• Chang, Steven Y
• Mallow, Christopher
• Rivas, Carolina
• Babcock, Hilary M
• Kwon, Jennie H
• Exline, Matthew C
• Halasa, Natasha
• Chappell, James D
• Lauring, Adam S
• Grijalva, Carlos G
• Rice, Todd W
• Jones, Ian D
• Stubblefield, William B
• Baughman, Adrienne
• Womack, Kelsey N
• Lindsell, Christopher J
• Hart, Kimberly W
• Zhu, Yuwei
• Mills, Lisa
• Lester, Sandra N
• Stumpf, Megan M
• Naioti, Eric A
• Kobayashi, Miwako
• Verani, Jennifer R
• Thornburg, Natalie J
• Patel, Manish M

Titel

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2021-09, Vol.70 (38), p.1337-1343

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged ≥18 years and aged ≥16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson & Johnson]) received EUA in February 2021 for persons aged ≥18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged ≥16 years on August 23, 2021 (4). Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine (4,5). To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged ≥18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2-6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. Patients with immunocompromising conditions were excluded. VE against COVID-19 hospitalizations was higher for the Moderna vaccine (93%; 95% confidence interval [CI] = 91%-95%) than for the Pfizer-BioNTech vaccine (88%; 95% CI = 85%-91%) (p = 0.011); VE for both mRNA vaccines was higher than that for the Janssen vaccine (71%; 95% CI = 56%-81%) (all p<0.001). Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination. Postvaccination anti-spike IgG and anti-RBD IgG levels were significantly lower in persons vaccinated with the Janssen vaccine than the Moderna or Pfizer-BioNTech vaccines. Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.